Beneficial Effect of Lenalidomide-Dexamethason Treatment in Relapsed/Refractory Multiple Myeloma Patients: Results of Real-Life Data From 11 Hungarian Centers

In Hungary, the cost of lenalidomide-based therapy is covered only for relapsed multiple myeloma (MM) patients, therefore lenalidomide is typically used in the second-line either as part of a triplet with proteasome inhibitors or as a doublet. Lenalidomide-dexamethasone is a standard treatment appro...

Descripción completa

Detalles Bibliográficos
Autores principales: Varga, Gergely, Dávid Tóth, András, Réka Szita, Virág, Csukly, Zoltán, Hardi, Apor, Gaál-Weisinger, Júlia, Nagy, Zsolt, Altai, Elvira, Rencsik, Annamária, Plander, Márk, Szendrei, Tamás, Kórád, Krisztina, Radványi, Gáspár, Rottek, János, Deák, Beáta, Szaleczky, Erika, Schneider, Tamás, Kohl, Zoltán, Kosztolányi, Szabolcs, Alizadeh, Hussain, Lengyel, Zsuzsanna, Modok, Szabolcs, Borbényi, Zita, Lovas, Szilvia, Váróczy, László, Illés, Árpád, Rajnics, Péter, Masszi, Tamás, Mikala, Gábor
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Society Journal Archive
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262242/
https://www.ncbi.nlm.nih.gov/pubmed/34257583
http://dx.doi.org/10.3389/pore.2021.613264

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8262242/
https://www.ncbi.nlm.nih.gov/pubmed/34257583
http://dx.doi.org/10.3389/pore.2021.613264

Ejemplares similares